The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib.
 
Alain Patrick Algazi
Stock and Other Ownership Interests - OncoSec; Valitor
Consulting or Advisory Role - Array BioPharma; OncoSec; Regeneron; Valitor
Research Funding - Acerta Pharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Idera (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Oncosec (Inst); OncoSec (Inst); Sensei Biotherapeutics (Inst); Tessa Therapeutics (Inst)
Travel, Accommodations, Expenses - OncoSec
(OPTIONAL) Uncompensated Relationships - Merck; Sensei Biotherapeutics
 
Megan Othus
Consulting or Advisory Role - Cascadia Labs; Celgene; Glycomimetics
 
Benjamin Newell Voorhies
No Relationships to Disclose
 
Kari Lynn Kendra
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Shaker R. Dakhil
No Relationships to Disclose
 
Amy K. Harker-Murray
Research Funding - Iovance Biotherapeutics (Inst)
 
Christopher D. Lao
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore
Research Funding - Bristol-Myers Squibb; Dynavax Technologies; Genentech; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immunocore
 
Bartosz Chmielowski
Consulting or Advisory Role - Array BioPharma; Biothera; Compugen; Deciphera; Epizyme; HUYA Bioscience International; IDEAYA Biosciences; Iovance Biotherapeutics; Janssen; Regeneron
Speakers' Bureau - Janssen Oncology; Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly/ImClone (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Rgenix (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Compugen; Deciphera; Epizyme; HUYA Bioscience International; IDEAYA Biosciences; Iovance Biotherapeutics; Regeneron
 
Roger Lo
Honoraria - Amgen
Research Funding - Array BioPharma (Inst); Array BioPharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Kenneth F. Grossmann
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Bristol-Myers Squibb (I); Castle Biosciences; Novartis; Roche/Genentech
 
Antoni Ribas
Stock and Other Ownership Interests - Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; ImaginAb; Lutris; Merus; PACT Pharma; Rgenix; Tango Therapeutics
Honoraria - Amgen; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)